Daiichi Sankyo taps new CEO, aims to build up ADC franchise

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.

Okuzawa is currently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Biophytis presented its phase 3 protocol in the treatment of sarcopenia – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis presented its phase 3 protocol in the treatment of sarcopenia 22-March-2024 / 07:01 CET/CEST Biophytis presented its phase 3

March 23, 2024

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

CAMBRIDGE, MA — When looking to the future of the drug industry, the allure of Boston is strong. This week, the Japanese drugmaker Astellas became

September 7, 2024

Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.